SCHEMBL23600548

SCHEMBL23600548

CN(c1cccc(-c2ccc(C(C)(C)O)cc2)c1)c1nc2nncn2c2cc(Cl)ccc12

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FNTA P49354 4/20 0.40
FNTB P49356 4/20 0.40
KCNH2 Q12809 2/20 0.35
NR4A2 P43354 1/20 0.35
TNKS O95271 2/20 0.34
PARP1 P09874 2/20 0.34
TNKS2 Q9H2K2 2/20 0.34
CCR9 P51686 1/20 0.33
CYP11B2 P19099 1/20 0.32
F10 P00742 1/20 0.32
CSNK2A2 P19784 1/20 0.32
CSNK2B P67870 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
MAT2A P31153 4/20 0.31
PTGES O14684 1/20 0.31
GRM2 Q14416 1/20 0.31
PRMT5 O14744 2/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31169406 1.00 FNTA (0.40) FNTAFNTBKCNH2NR4A2TNKS
SCHEMBL23577059 0.93 FNTA (0.41) FNTAFNTBCCR9TP53MAPT
SCHEMBL29909922 0.93 FNTA (0.41) FNTAFNTBCCR9TP53MAPT
SCHEMBL31229690 0.91 FNTA (0.41) FNTAFNTBCSNK2A2CSNK2BTP53
SCHEMBL23577102 0.91 FNTA (0.41) FNTAFNTBCSNK2A2CSNK2BTP53
SCHEMBL23601235 0.91 FNTA (0.40) FNTAFNTBF10CSNK2A2CSNK2B
SCHEMBL29909768 0.91 FNTA (0.40) FNTAFNTBF10CSNK2A2CSNK2B
SCHEMBL23601905 0.90 FNTA (0.40) FNTAFNTBTP53MAPTMAT2A
SCHEMBL23601858 0.90 FNTA (0.39) FNTAFNTBF10CSNK2A2CSNK2B
SCHEMBL31229755 0.90 FNTA (0.39) FNTAFNTBF10CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK FNTA 968/4885FNTB 743/4885KCNH2 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.